Use of a depot steroid formulation with CHOP-based protocol in the treatment of mediastinal lymphoma in cats

Document Type: Scientific report

Authors

1 MSc, Hospital Animal Bluecare Mijas, Spain

2 Internal Medicine, Faculty of Veterinary Medicine, University Institute for Biomedical and Health Research (IUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain

3 MSc, Centro de Diagnóstico Veterinario, Valladolid, Spain

4 MSc, Sheriff Highway Newcastle, UK

5 BSc, Northside Vets Birmingham, UK

Abstract

The aims of this retrospective study were to evaluate the efficacy of different steroid formulations (depot vs oral) and if the continuous administration of steroids throughout and beyond a CHOP protocol might improve the survival time and rate of cats with mediastinal lymphoma. The medical records of client-owned cats diagnosed with mediastinal lymphoma were reviewed at two veterinary referral hospitals in Spain. Cases were recruited from 2008 to 2016. Those cats with mediastinal lymphoma treated with chemotherapy were used in the collection of data including surgical procedures, chemotherapy protocol, side effects, complete remission (CR), partial remission and survival time were calculated from time of diagnosis. The median survival time (MST) of group with depot steroid was 370.7 days and all cats are still alive. The MST of group with oral steroid was 267.9 days. The survival distributions were found to be significantly different. The use of depot injectable steroids with a CHOP-based protocol seems to result in a longer survival time in patients with mediastinal lymphoma when comparing the survival distribution for those receiving oral steroids with a CHOP-based protocol. Prospective studies with a higher number of cats are warranted to investigate the utility of injectable steroids depot with a CHOP-based protocol in the treatment of mediastinal lymphoma. 

Keywords


Chun, R (2009). Lymphoma: which chemotherapy protocol and why? Top Companion Anim. Med., 24: 157-162.

Court, EA; Watson, AD and Peaston, AE (1997). Retrospective study of 60 cases of feline lymphosarcoma. Aust. Vet. J., 75: 424-427.

Dorn, CR; Taylor, DO and Hibbard, HH (1967). Epizootiologic characteristics of canine and feline leukemia and lymphoma. Am. J. Vet. Res., 28: 993-1001.

Ettinger, SN (2003). Principles for treatment of feline lymphoma. Clin. Tech. Small Anim. Prac., 18: 98-102.

Fabrizio, F; Calam, AE; Dobson, JM; Middleton, SA; Murphy, S; Taylor, SS; Schwartz, A and Stell, AJ (2013). Feline mediastinal lymphoma: a retrospective study of signalment, retroviral status, response to chemotherapy and prognostic indicators. J. Fel. Med. Surg., 16: 637-644.

Fox, LE (2003). Therapeutic choices for the medical management of feline lymphoma. Waltham Feline Medicine Symposium. Orlando, Florida. USA.

Gabor, LJ; Jackson, ML; Trask, B; Malik, R and Canfield, PJ (2001). Feline leukaemia virus status of Australian cats with lymphosarcoma. Aust. Vet. J., 79: 476-481.

Gabor, LJ; Malik, R and Canfield, PJ (1998). Clinical and anatomical features of lymphosarcomain 118 cats. Aust. Vet. J., 76: 725-732.

Garrett, LD; Thamm, DH; Chun, R; Dudley, R and Vail, DM (2002). Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J. Vet. Intern. Med., 16: 704-709.

Hahn, KA; Richardson, RC; Teclaw, RF; Cline, JM; Carlton, WW; DeNicola, DB and Bonney, PL (1992). Is maintenance chemotherapy appropriate for the management of canine malignant lymphoma? J. Vet. Intern. Med., 6: 3-10.

Kristal, O; Lana, SE; Ogilvie, GK; Rand, WM; Cotter, SM and Moore, AS (2001). Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994-1997). J. Vet. Intern. Med., 15: 125-130.

Louwerens, M; London, CA; Pedersen, NC and Lyons, LA (2005). Feline lymphoma in the post-feline leukemia virus era. J. Vet. Intern. Med., 19: 329-335.

Milner, RJ; Pearson, J; Nesbit, JW and Close, P (1996). Immunophenotypic classification of canine malignant lymphoma on formalin-mixed paraffin wax-embedded tissue by means of CD3 and CD79a cell markers. Onderstepoort J. Vet. Res., 63: 309-313.

Mooney, SC; Hayes, AA; MacEwen, EG; Matus, RE; Geary, A and Shurgot, BA (1989). Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981). J. Am. Vet. Med. Assoc., 194: 696-702.

Mooney, SC; Hayes, AA; Matus, RE and MacEwen, EG (1987). Renal lymphoma in cats: 28 cases (1977-1984). J. Am. Vet. Med. Assoc., 191: 1473-1477.

Ramsey, I (2011). BSAVA small animal formulary. 7th Edn., Wiley Publication. PP: 255-256.

Shih, JL; Brenn, S and Schrope, DP (2014). Cardiac involvement secondary to mediastinal lymphoma in a cat: regression with chemotherapy. J. Vet. Card., Accessed 01 Februrary 2017. http://dx.doi.org/10.1016/j.jvc.


Simon, D; Naranjo Moreno, S; Hirschberger, J; Moritz, A; Kohn, B; Neumann, S; Jurina, K; Scharvogel, S; Schwedes, C; Reinacher, M; Beyerbach, M and Nolte, I (2008). Efficacy of a continuous, multiagent chemo-therapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J. Am. Vet. Med. Assoc., 232: 879-885.

Starrak, GS; Berry, CR; Page, RL; Johnson, JL and Thrall, DE (1997). Correlation between thoracic radiographic changes and remission/survival duration in 270 dogs with lymphosarcoma. Vet. Radiol. Ultrasound. 38: 411-418.

Thamm, DH (2014). Lymphoma: advances in treatment. ABVP (The American Board of Veterinary Practitioners). Nashville, Tennessee, USA.

Vail, DM (2012). Feline lymphoma and leukemia. In: Withrow, SJ and Vail, DM (Eds.), Small animal clinical oncology. (3rd Edn.), Missouri: Saunders. PP: 733-755.

Vail, DM; Moore, AS; Ogilvie, GK and Volk, LM (1998). Feline lymphoma (145 cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. J. Vet. Intern. Med., 12: 349-354.

Valli, VE; Jacobs, RM; Norris, A; Couto, CG; Morrison, WB; McCaw, D; Cotter, S; Ogilvie, G and Moore, A (2000). The histologic classification of 602 cases of feline lymphoproliferative disease using the National Cancer Institute working formulation. J. Vet. Diag. Invest., 12: 295-306.

Waite, AH; Jackson, K; Gregor, TP and Krick, EL (2013). Lymphoma in cats treated with a weekly cyclo-phosphamide, vincristine, and prednisone-based protocol: 114 cases (1998-2008). J. Am. Vet. Med. Assoc., 242: 1104-1109.